Spanish regulators suspend Inmunotek's manufacturing license and order recall

By Gareth Macdonald contact

- Last updated on GMT

Spanish regulators suspend Inmunotek's manufacturing license and order recall

Related tags: Immune system

Inmunotek has been ordered to recall vaccines made at a facility in Madrid after Spanish regulators identified a number of GMP deficiencies.

The Spanish Agency of Medicines and Medical Devices (AEMPS) ordered​ the recall and suspended the San Sebastian de los Reyes site’s manufacturing license after identifying a number of problems.

The deficiencies detected on the last inspection carried out on 15-16/03/2016 impact on the Quality system of the site and the manufacturing process of sterile immunological products.”

The quality, and especially the sterility of the products manufactured cannot be assured. As a consequence of this and to prevent risk for the patients, AEMPS has decided to suspend the site´s manufacturer authorization for finished products until the implementation of necessary corrective/preventive actions​.”

Operations at Immunotek’s other manufacturing facility in Alcala de Henares – also in Madrid – are unaffected. Details of the recalled vaccines were not disclosed.

Inmunotek describes itself as a supplier of anti-allergy and immunology products.


Miguel Casanovas, Inmunotek medical director, told us “the Spanish Authorities temporally suspended the manufacturing authorization of our facilities in San Sebastián de los Reyes based on documentary inspection​.”

He added the site was closed for maintenance at the time of the AEMPS inspection and stressed that “this alert is due to a documental inspection and not, in any case, due to the analysis of the product by the authorities or to an adverse reaction of infectious complications after the administration of these allergen vaccines​.”

AEMPS did not respond to a request for more information.

Related topics: Markets & Regulations, QA/QC, Regulations

Related news

Show more

Related products

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Related suppliers

Follow us


View more